Loading...
Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.
Buzzoni, R Carnaghi, C Strosberg, J Fazio, N Singh, S Herbst, F Ridolfi, A Pavel, M Wolin, E Valle, Juan W
Buzzoni, R
Carnaghi, C
Strosberg, J
Fazio, N
Singh, S
Herbst, F
Ridolfi, A
Pavel, M
Wolin, E
Valle, Juan W
Citations
Altmetric:
Abstract
Recently, everolimus was shown to improve median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) tract compared with placebo (HR, 0.48; 95% CI, 0.35-0.67; P<0.00001) in the Phase III, RADIANT-4 study. This post hoc analysis evaluates the impact of prior therapies (somatostatin analogs [SSA], chemotherapy, and radiotherapy) on everolimus activity.
Description
Date
2017
Publisher
Collections
Files
Keywords
Type
Article
Citation
Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. 2017, 10:5013-5030 Onco Targets Ther